Australia markets open in 1 hour 47 minutes

Calidi Biotherapeutics, Inc. (CLDI)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.2360-0.0121 (-4.88%)
At close: 04:00PM EDT
0.2385 +0.00 (+1.06%)
After hours: 06:08PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.63M
Enterprise value 23.20M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)50.83
Price/book (mrq)N/A
Enterprise value/revenue 49.42
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-97.61%
S&P500 52-week change 328.04%
52-week high 313.7900
52-week low 30.1440
50-day moving average 30.3889
200-day moving average 32.5223

Share statistics

Avg vol (3-month) 31.07M
Avg vol (10-day) 3304.14k
Shares outstanding 550.92M
Implied shares outstanding 650.92M
Float 822.19M
% held by insiders 138.55%
% held by institutions 15.62%
Shares short (30 Apr 2024) 445.57k
Short ratio (30 Apr 2024) 40.02
Short % of float (30 Apr 2024) 40.12%
Short % of shares outstanding (30 Apr 2024) 40.09%
Shares short (prior month 28 Mar 2024) 4149.02k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-242.04%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -29.93M
Net income avi to common (ttm)-29.98M
Diluted EPS (ttm)-0.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.14M
Total cash per share (mrq)0.03
Total debt (mrq)11.51M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.13
Book value per share (mrq)-0.41

Cash flow statement

Operating cash flow (ttm)-27.71M
Levered free cash flow (ttm)-44.86M